342 results about "Endothelium" patented technology

The invention discloses composite hydrogel bio-ink with a function of space-time delivery of double growth factors as well as a preparation method and application of the composite hydrogel bio-ink, and belongs to the technical field of biomedical materials and tissue engineering. According to the preparation method, imidazolyl-modified methacrylated gelatin and double-bonded PF127 are compounded, and meanwhile, free vascular endothelial growth factors and connective tissue growth factor-loaded PLGA microspheres are entrapped in a system, so that the bio-ink with excellent printability, high adhesion, swelling resistance and space-time delivery function is formed; the bio-ink physically has the advantages of high printing fidelity, low swelling property, high mechanical strength and strong tissue adhesion of a synthetic material; in biology, the system can be used as an intelligent carrier to realize programmed space-time delivery of various growth factors, so that complex cell biological behaviors are accurately arranged, and real regeneration of functional tissues is guided.

The invention relates to the technical field of biomedical materials, in particular to a double-network structure artificial blood vessel with anticoagulation, endothelium promotion and anti-infection functions and a preparation method of the double-network structure artificial blood vessel. The artificial blood vessel comprises a polymer fiber network artificial blood vessel substrate, a microscopic network hydrogel layer penetrating through the polymer fiber network artificial blood vessel substrate, and magnesium-copper alloy particles doped in the hydrogel layer. According to the artificial blood vessel with the double-network structure, the problem that a traditional small-caliber artificial blood vessel is insufficient in mechanical performance is greatly solved, copper ions and magnesium ions are released to the surrounding environment by means of degradation of the magnesium-copper alloy particles in the using process, the microenvironment of the surrounding tissue is adjusted to be alkalescent, nitric oxide is catalytically released, and the mechanical performance of the artificial blood vessel is improved. The artificial blood vessel with the double-network structure is endowed with anticoagulation, endothelium promotion and anti-infection functions. The problems of restenosis and insufficient endothelialization of a small-caliber artificial blood vessel in the prior art are comprehensively solved, and the long-term patency rate of the artificial blood vessel is increased.

According to the invention, lactobacillus rhamnosus UP180 with relatively strong cellulase activity and lactobacillus paracasei ID001 with relatively strong protease activity are combined to prepare composite probiotic powder, the composite probiotic powder is used for jointly fermenting the endothelium corneum gigeriae galli formula, and meanwhile, a polypeptide capable of improving the digestive enzyme activity of Caco-2 cells is found from a fermentation product. The compound strain fermentation effectively decomposes macromolecular proteins in the endothelium corneum gigeriae galli formula and converts the macromolecular proteins into small molecular peptides, effective active ingredients in the formula are fully released, and the conversion effect is obviously superior to that of single strain fermentation. Besides, the endothelium corneum gigeriae galli composition leavening prepared by the invention can improve nutrient absorption of the rats by improving enzyme activity and metal ion chelation in intestinal tracts of the rats in the weaning period and promote growth of the rats in the weaning period, and has a potential application prospect in the field of nutrient absorption of children.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating gastroesophageal reflux cough and a preparation method thereof. The traditional Chinese medicine composition disclosed by the invention is constructed by carefully selecting a medicine formula under the guidance of a traditional Chinese medicine theory and clinical experience and through a compatibility theory of monarch, minister, assistant and guide of traditional Chinese medicines. In the traditional Chinese medicine composition, the inula flower has the effects of promoting blood circulation, removing stasis and turbidity, clearing the airway and removing phlegm and fluid retention, and the mangnolia officinalis has the effects of promoting qi circulation, removing food retention, calming adverse-rising energy and relieving asthma, and both serve as monarch drugs; the dried orange peel has the effects of regulating qi and removing stagnation, the poria cocos has the effects of tonifying spleen, eliminating dampness and phlegm and breaking up the source of phlegm, and the bulbus fritillariae cirrhosae has the effects of clearing heat and moistening lung and resolving phlegm and relieving asthma; the rhizoma atractylodis macrocephalae has the effects of invigorating the spleen, replenishing qi, eliminating dampness and inducing diuresis, and the endothelium corneum gigeriae galli has the effects of promoting digestion and invigorating the stomach and is an assistant and guide drug. The whole prescription is ordered in monarch and minister, focuses on pathogenesis, is rigorous in prescription, has the effects of relieving cough and asthma, clearing heat and moistening lung, and strengthening spleen and stomach, and treats both symptoms and root causes of cough.

This utility model relates to an innovation of a carotid artery vasodilator that can be used at home and in the emergency room as a supplement to drug treatment for conditions such as carotid artery obstruction in the neck region. It increases the production of nitric oxide mediated by endothelial nitric oxide synthase in the intact endothelial layer of the carotid artery, which is located on the inner surface of the neck brace. It can be applied for a certain period of time for each patient. The intermittent or continuous operation function can be selected through an adjustable power circuit. It only affects the lesion area and does not affect the patient's peripheral blood vessels. It can be used in situations where nitrates may be prohibited. It prevents the reduction of blood flow to the brain tissue that may occur due to jugular venous constriction. The flexible structure of the applicator neck brace (9) can be maintained in the application area for a long time and includes a pulsed magnetic field (PMF).

The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention relates to a medical device for treating aneurysms, in particular a stent, including a compressible and expandable grid structure made up of grid elements. The grid structure has at least one closed cell ring which includes at most 12, in particular at most 10, in particular at most 8, in particular at most 6 cells directly adjacent to one another in a circumferential direction of the grid structure. The grid structure is provided at least in certain portions with a covering made of an electrospun fabric which has pores of irregular sizes. The covering includes over a surface area of 100 000 μm2 at least 10 pores which have a size of at least 15 μm2. The covering has a biocompatible, in particular antithrombogenic and / or endothelialization-promoting coating.

The present invention is concerned with a protein oligomer comprising (i) at least two NC-1 monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and / or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The application discloses an AMD efficacy prediction method, system, device and medium based on feature fusion, belongs to the technical field of efficacy prediction, and comprises the following steps: acquiring optical coherence tomography image data and demographic characteristics of an age-related macular degeneration patient; determining deep learning features and imaging features according to the optical coherence tomography image data; performing feature selection based on the deep learning features, the imaging features and the demographic characteristics to obtain input features; performing calculation by combining a time series analysis network with the input features to determine a hidden state; and performing feature change trend analysis according to the hidden state to determine an age-related macular degeneration efficacy prediction result. The application proposes a multi-feature fusion long short-term memory network, and realizes efficacy prediction of anti-vascular endothelial growth factor treatment for the age-related macular degeneration patient.

This invention provides a near-infrared therapy device for improving Alzheimer's disease, characterized by comprising: a frequency-modulated drive circuit 1, a near-infrared LD light source 2, an optical fiber coupler 3, a light source power monitoring photodetector (PD) 4, an optical power monitoring circuit 5, an optical fiber beam splitter 6, an MPO optical fiber cable 7, and an optical transmitter 8. The optical transmitter includes an optical transmitter housing 8-1, a fiber-end hemispherical emitting microlens 8-2, and a beam-shaping coupling lens 8-3. This invention can be used to regulate the metabolism and cellular function of meningeal lymphatic endothelial mitochondrial cells, promote meningeal lymphatic transport in the central nervous system, thereby alleviating the pathological symptoms of Alzheimer's patients and enhancing their cognitive function. The device has a simple and compact structure, is easy to plug and unplug, has low optical signal loss, and high coupling efficiency. It can be widely used in novel non-invasive optical brain-computer interface devices and belongs to the field of fiber optic sensing technology.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

The invention provides a blood concentration prediction model based on artificial intelligence and a construction method and application thereof.A whole blood sample of a patient taking sirolimus is collected, the blood concentration is detected through liquid chromatography tandem mass spectrometry, CYP 3A4 / 5, CYP 2C8 and P-gp gene polymorphism is detected in combination with a high-resolution dissolution curve technology, and the blood concentration prediction model based on artificial intelligence is obtained. And constructing a database containing the multi-dimensional data. And training the database by using an extreme gradient lifting algorithm, establishing a high-precision sirolimus blood concentration artificial intelligence prediction model, and developing a mobile equipment end application to realize remote data acquisition and result display. The model is especially suitable for children with Carboxi-like vascular endothelioma, can dynamically monitor the blood concentration in real time, provides refined guidance for clinical treatment, reduces the treatment cost, and improves the treatment effect and safety.

Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting human ANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.

The present application relates to deoxyvaccinum ketone compound and its preparation method and anti-inflammatory application, belong to the medical technical field.The deoxyvaccinum ketone compound provided in the present application can reduce the expression of inflammatory factors in RAW 264.7 cell inflammation model, and the deoxyvaccinum ketone compound ZZMV-17 can reduce neutrophil infiltration, inflammatory factor cascade release and endothelial injury by antagonizing CXCR2 receptor, so as to achieve the anti-inflammatory effect;In summary, the deoxyvaccinum ketone compound can antagonize CXCR2 receptor, regulate downstream signal pathways such as NF-κB, reduce neutrophil infiltration, reduce the release of inflammatory factors, and has great clinical application value.

The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.

The invention relates to application of IGFBP7 in clinical diagnosis of colorectal cancer and application of IGFBP7 as a drug target. The research shows that the expression quantity of IGFBP7 secreted by tumor endothelial cells is continuously reduced in the colorectal tumor formation process related to inflammation. Functional analysis proves that the endothelial-derived IGFBP7 is secreted into a tumor microenvironment and plays a role in resisting angiogenesis. In addition, the CRC cells can actively ingest the vesicles containing the IGFBP7. The IGFBP7 reduces the activity of a TGF-beta1 signal channel by inhibiting the expression of EGR1, thereby inhibiting the proliferation and migration of tumor cells. What is worthy of attention is that VAPA (Vesicle-associated Membrane Protein Associated Protein A) is identified to be a key factor for mediating IGFBP7 vesicles to be transferred to lysosome, and VAPA promotes the degradation of IGFBP7, so that the cancer suppression function of the IGFBP7 is weakened. The endothelial cell-derived IGFBP7 inhibits the progress of CRC (cyclic redundancy check) through an EGR1 / TGF-beta 1 pathway, and VAPA-mediated lysosome degradation limits the cancer inhibition effect of the endothelial cell-derived IGFBP7. The discovery emphasizes that the endothelial cell-derived IGFBP7 is a promising therapeutic target in the field of colorectal cancer.

The invention relates to the technical field of traditional Chinese medicine compositions and preparations, in particular to a traditional Chinese medicine composition for treating liver depression and spleen deficiency type chronic gastritis and a preparation method thereof. The traditional Chinese medicine composition is prepared from codonopsis pilosula, rhizoma atractylodis macrocephalae stir-fried with bran, radix bupleuri, stir-fried radix paeoniae alba, pericarpium citri reticulatae, fructus aurantii stir-fried with bran, ginger processed pinellia, radix salviae miltiorrhizae, medicated leaven, stir-fried endothelium corneum gigeriae galli and fingered citron according to The traditional Chinese medicine composition is based on the theory of inhibiting wood and supporting soil in traditional Chinese medicine, and all the components have a synergistic effect and have the effects of soothing the liver, relieving depression, strengthening the spleen and harmonizing the stomach. Animal experiments prove that the traditional Chinese medicine composition provided by the invention can significantly improve the gastric emptying rate and the small intestine propulsion rate of a chronic gastritis model, and can down-regulate the gene expression of gastric mucosa intestinal metaplasia related markers CDX2 and MUC2.

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

This invention belongs to the field of biomedical technology, specifically relating to a madder-derived exosome-like nanovesicle, an artificial blood vessel, and their preparation and application. This invention utilizes differential centrifugation and sucrose density gradient centrifugation techniques to extract high-purity, highly active exosome-like nanovesicles from madder. Then, polydopamine is loaded onto the surface of a small-diameter polyurethane artificial blood vessel, which is then immersed in a suspension of madder-derived exosome-like nanovesicles to obtain a small-diameter artificial blood vessel loaded with madder-derived exosome-like nanovesicles. These madder-derived exosome-like nanovesicles can effectively promote endothelial cell proliferation and inhibit reactive oxygen species generation; animal experiments show unobstructed blood flow under ultrasound. The small-diameter artificial blood vessel loaded with madder-derived exosome-like nanovesicles can simultaneously achieve in vivo endothelialization and vascular patency, possessing significant clinical application value.

This invention relates to a left atrial appendage occlusion device, comprising an occlusion disc, a connecting mechanism, and a filling module. The occlusion disc is connected to the filling module via the connecting mechanism. The filling module includes at least one filling unit, and all the filling units are connected in series. The filling module is used to fill the entire interior of the left atrial appendage. By setting the occlusion disc and the filling module, the number and size of the filling units in the filling module can be customized according to the shape of the lesion in the left atrial appendage, so as to better fill the lesion space and achieve the effect of occlusion of the left atrial appendage in conjunction with the occlusion disc. By setting polyurethane foam in the occlusion disc, thrombus formation and occlusion can be quickly achieved and the endothelialization process can be accelerated. At the same time, the filling unit made of polyurethane foam can also accelerate the closure of the entire chamber.

Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.

The invention discloses a culture method based on posthypoxia gastric intima separation treatment of freshwater white pomfret, and relates to the technical field of aquaculture and disease prevention and control. The method comprises the following steps: step 1, identifying hypoxia symptoms; 2, medicine compatibility feeding is carried out; 3, regulating and controlling the water body environment; 4, breeding environment management; and step 5, continuous monitoring. According to the invention, the food maternal, the endothelium corneum gigeriae galli and the pipemidic acid are combined for the separation treatment of the endogastric membranes of the aquatic animals for the first time, the thinking limitation of traditional disease prevention and treatment is broken through, the traditional Chinese and western medicine theories are organically combined, and a new disease prevention and treatment thought is provided for the aquaculture industry; compared with a traditional pure antibiotic treatment or water quality improvement method, the scheme is high in pertinence and directly aims at a core pathological link of gastric intima separation after hypoxia; the comprehensive treatment effect is good, and meanwhile, anti-infection, mucous membrane repair and function regulation are considered; and the used medicines are all common medicines, have small side effects and low residues, and meet the safety requirements of aquatic products.

The application discloses a plugging device and relates to the technical field of medical devices. The plugging device comprises a plugging body, an elastic connecting piece and a hanging component. The plugging body is adapted to the shape of a target plugging area. One end of the elastic connecting piece is arranged on the plugging body. One end of the hanging component is connected with the other end of the elastic connecting piece, and the hanging component is adapted to be hung on the tissue of the target plugging area. The plugging device for cauliflower-shaped left atrial appendages is made of degradable materials, can be implanted into the left atrial appendages of a patient through a minimally invasive catheter intervention operation to realize plugging of the left atrial appendages, can guide the climbing of the endothelial tissue in the left atrium, and can realize complete degradation of the device in the human body after endothelialization. Finally, the plugging effect is realized by the patient's autologous tissue, the formation and shedding of thrombus embolus in the left atrial appendages are effectively prevented, and the risk of stroke is greatly reduced.

The present application relates to a left atrial appendage occluder, comprising: an expandable frame transitionable between a compressed state and an expanded state; a covering membrane arranged along at least part of the outer surface of the expandable frame; a connecting structure arranged at the proximal end of the expandable frame and being connectable to and disconnectable from a conveying system; and an anticoagulant coating arranged only on at least part of the outer surface of the covering membrane. The present application can reduce the risk of thrombus formation on the surface of the left atrial appendage occluder and accelerate the endothelialization process.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a composition in the preparation of a drug for treating diabetic wounds. The composition comprises the following components: *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone, with a mass ratio of 1:0.1-0.25:0.02-0.05. In this composition, *Artemisia capillaris* exosomes can penetrate the thickened inflammatory exudate layer and glycosylated extracellular matrix of diabetic wounds, reshaping the wound's immune repair microenvironment, promoting fibroblast activation and proliferation, regulating collagen synthesis and deposition, and reducing scar hyperplasia. 3-hydroxymorinogenone can increase vascular endothelial growth factor, promote angiogenesis, and thus promote the repair and healing of diabetic wounds. The synergistic effect of *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone in this composition significantly shortens the healing cycle of difficult-to-heal diabetic wounds and improves the quality of wound healing.

Various methods for isolating cell populations from adipocyte tissue and / or blood and quantifying levels of vascular endothelial growth factor receptors (VEGFR) on the isolated cell populations are provided. Also provided are methods of evaluating or modifying angiogenic therapy in a subject.

The invention relates to a preparation process of near-infrared fluorescent powder, in particular to nickel-containing near-infrared fluorescent powder and a preparation method thereof, a certain amount of barium carbonate, gallium oxide, nickel oxide and isopropanol are taken to be prepared into turbid liquid, and the nickel-containing barium gallate-based near-infrared fluorescent powder is prepared through the steps of grinding, drying, grinding, pressing, heat treatment, cooling, grinding and the like. Under the excitation of 635 nm light, the fluorescent powder presents ultra-wide band near-infrared luminescence composed of 1050-1400 nm light emission derived from matrix defects and 1300-1800 nm light emission of Ni < 2 + > ions; the light-emitting diode light source is more suitable for compact special near-infrared fluorescent powder conversion light-emitting diode light source design for high-resolution deep biological tissue imaging diagnosis equipment. Similarly, due to no ionizing radiation ultra-wide band NIR-II region emission, the system can be used in various biological tissue situations such as fat, muscle, endothelium and the like, and then development of multipurpose imaging diagnostic analysis technologies and equipment which are suitable for family daily medical treatment and are friendly and safe to special groups such as children, pregnant women, old people and the like can be promoted.